Beta DrugsNSE:BETA -3.13%82 Piotroski F-Score is 4 as of Jun. 27, 2026, which is 33% below its 10-year median of 6.00. GuruFocus rates NSE:BETA with a GF Score™ of 82/100 and a GF Value™ of ₹1,960.95 (Fairly Valued). The stock has 6 warning signs investors should review. Among 981 Drug Manufacturers companies, Beta Drugs ranks worse than 61.06% on this metric.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Beta Drugs has an F-score of 4 indicating the company's financial situation is typical for a stable company.
The historical rank and industry rank for Beta Drugs's Piotroski F-Score or its related term are showing as below:
NSE:BETA'
s Piotroski F-Score Range Over the Past 10 Years
Min: 3 Med: 6 Max: 8
Current: 4
During the past 13 years, the highest Piotroski F-Score of Beta Drugs was 8. The lowest was 3. And the median was 6.
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Beta Drugs Piotroski F-Score Related Terms
Beta Drugs Piotroski F-Score Historical Data
* Premium members only.
The historical data trend for Beta Drugs's Piotroski F-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Beta Drugs's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beta Drugs Piotroski F-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beta Drugs's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Beta Drugs's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Beta Drugs's current Net Income (TTM) was 415.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Beta Drugs's return on assets of this year was 0.09509262. Beta Drugs's return on assets of last year was 0.16693756.
==> Last year is higher ==> Score 0.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Beta Drugs's gearing of this year was 0.28609398. Beta Drugs's gearing of last year was 0.36792199.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Beta Drugs's current ratio of this year was 3.09931071. Beta Drugs's current ratio of last year was 3.22280044.
==> Last year's current ratio is higher ==> Score 0.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Beta Drugs's number of shares in issue this year was 10.138. Beta Drugs's number of shares in issue last year was 10.095.
==> There is larger number of shares in issue this year. ==> Score 0.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Beta Drugs's gross margin of this year was 0.55517561. Beta Drugs's gross margin of last year was 0.527113.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Beta Drugs's asset turnover of this year was 0.88215312. Beta Drugs's asset turnover of last year was 1.42604367.
==> Last year's asset turnover is higher ==> Score 0.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
1
+
1
+
0
+
0
+
1
+
0
+
0
+
1
+
0
=
4
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Beta Drugs has an F-score of 4 indicating the company's financial situation is typical for a stable company.
Beta Drugs (NSE:BETA) has a Piotroski F-Score of 4 as of Jun. 27, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Beta Drugs and its competitors. This is 33% below median its historical median of 6.00. Over the past decade, Beta Drugs' Piotroski F-Score has ranged from 3.00 to 8.00. According to the industry distribution chart, Beta Drugs ranks #599 out of 981 companies in the Drug Manufacturers industry, placing it in the top 61.1%.
Is Beta Drugs' Piotroski F-Score too high?
Beta Drugs' current Piotroski F-Score of 4 is 33% below median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 8.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Beta Drugs' value of 4 is 20% below this industry median. Based on the distribution chart, Beta Drugs ranks #599 out of 981 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Beta Drugs has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beta Drugs' Piotroski F-Score compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Beta Drugs ranks #599 out of 981 companies for Piotroski F-Score. This places Beta Drugs in the lower half of its industry. The industry median Piotroski F-Score is 5.00. Beta Drugs' value of 4 is 20% below this benchmark. Historically, Beta Drugs' own Piotroski F-Score has ranged from 3.00 to 8.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Beta Drugs has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beta Drugs's current Piotroski F-Score of 4 is 20% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Beta Drugs and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beta Drugs's current Piotroski F-Score is 4, which is 33% below median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beta Drugs stock overvalued right now?
Based on GuruFocus' analysis, Beta Drugs (NSE:BETA) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,960.95, compared to a current price of ₹2,096.60 — trading 6.9% above its estimated fair value. The current Piotroski F-Score is 4, which is 33% below median its 10-year median of 6.00 and 20% below the Drug Manufacturers industry median of 5.00. Beta Drugs' overall GF Score™ is 82/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Beta Drugs (NSE:BETA), the current Piotroski F-Score is 4 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Beta Drugs (NSE:BETA) Overvalued in 2026?
Based on GuruFocus' analysis, Beta Drugs stock appears to be overvalued.
The current stock price of ₹2,096.60 is trading 6.9% above its estimated GF Value™ of ₹1,960.95.
GuruFocus considers Beta Drugs to be Fairly Valued.
Key valuation signals for NSE:BETA:
Piotroski F-Score: 4 (33% below median its 10-year median of 6.00)
GF Value™: ₹1,960.95 vs. price of ₹2,096.60 (6.9% above fair value)
Industry Position: 20% below the Drug Manufacturers median (#599 of 981)
No single metric tells the full story. See the NSE:BETA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Beta Drugs Ltd operates in the pharmaceutical industry. The company manufactures and sells Oncology products in the form of tablets, capsules, oral formulations, and injections. It sells the products in India and also exports them to other countries, of which key revenue is derived from the sales made in India.
82GF Score
Get the complete analysis for NSE:BETA
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BETA has been successfully added to your 
